The Path to Clinical Proteomics Research: Integration of Proteomics, Genomics, Clinical Laboratory and Regulatory Science.
10.3343/kjlm.2011.31.2.61
- Author:
Emily S BOJA
1
;
Henry RODRIGUEZ
Author Information
1. Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. rodriguezh@mail.nih.gov
- Publication Type:Review
- Keywords:
Quantitative proteomics;
Biomarker;
Multiplex protein assays;
MRM-MS;
Immunoassays
- MeSH:
Biological Markers/analysis;
Clinical Laboratory Techniques/standards;
*Genomics;
Humans;
Mass Spectrometry/methods/standards;
Neoplasms/*diagnosis/genetics;
*Proteomics;
Quality Control;
United States;
United States Food and Drug Administration
- From:The Korean Journal of Laboratory Medicine
2011;31(2):61-71
- CountryRepublic of Korea
- Language:English
-
Abstract:
Better biomarkers are urgently needed to cancer detection, diagnosis, and prognosis. While the genomics community is making significant advances in understanding the molecular basis of disease, proteomics will delineate the functional units of a cell, proteins and their intricate interaction network and signaling pathways for the underlying disease. Great progress has been made to characterize thousands of proteins qualitatively and quantitatively in complex biological systems by utilizing multi-dimensional sample fractionation strategies, mass spectrometry and protein microarrays. Comparative/quantitative analysis of high-quality clinical biospecimen (e.g., tissue and biofluids) of human cancer proteome landscape has the potential to reveal protein/peptide biomarkers responsible for this disease by means of their altered levels of expression, post-translational modifications as well as different forms of protein variants. Despite technological advances in proteomics, major hurdles still exist in every step of the biomarker development pipeline. The National Cancer Institute's Clinical Proteomic Technologies for Cancer initiative (NCI-CPTC) has taken a critical step to close the gap between biomarker discovery and qualification by introducing a pre-clinical "verification" stage in the pipeline, partnering with clinical laboratory organizations to develop and implement common standards, and developing regulatory science documents with the US Food and Drug Administration to educate the proteomics community on analytical evaluation requirements for multiplex assays in order to ensure the safety and effectiveness of these tests for their intended use.
